These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 27567832

  • 1. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
    van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW, European DLB consortium.
    J Alzheimers Dis; 2016 Aug 18; 54(1):287-95. PubMed ID: 27567832
    [Abstract] [Full Text] [Related]

  • 2. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, De Roeck N, Tambasco N, Stoops E, Vanderstichele H, Engelborghs S, Mollenhauer B, Calabresi P, Parnetti L.
    Alzheimers Res Ther; 2017 Jul 28; 9(1):52. PubMed ID: 28750675
    [Abstract] [Full Text] [Related]

  • 3. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.
    Biol Psychiatry; 2008 Nov 15; 64(10):850-5. PubMed ID: 18395699
    [Abstract] [Full Text] [Related]

  • 4. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.
    Geng C, Tan L, Chen C.
    Brain Res; 2024 Jun 15; 1833():148881. PubMed ID: 38519009
    [Abstract] [Full Text] [Related]

  • 5. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T, Sawada J, Kikuchi-Takeguchi S, Kano K, Takahashi K, Saito T, Okizaki A, Hasebe N.
    Neurosci Lett; 2020 Jan 10; 715():134564. PubMed ID: 31733322
    [Abstract] [Full Text] [Related]

  • 6. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D.
    J Neurol Neurosurg Psychiatry; 2011 Feb 10; 82(2):160-4. PubMed ID: 21047883
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F.
    J Alzheimers Dis; 2016 Feb 10; 51(4):1069-83. PubMed ID: 26923009
    [Abstract] [Full Text] [Related]

  • 8. Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.
    Gmitterová K, Gawinecka J, Llorens F, Varges D, Valkovič P, Zerr I.
    Eur Arch Psychiatry Clin Neurosci; 2020 Jun 10; 270(4):461-470. PubMed ID: 30083957
    [Abstract] [Full Text] [Related]

  • 9. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
    Bolsewig K, van Unnik AAJM, Blujdea ER, Gonzalez MC, Ashton NJ, Aarsland D, Zetterberg H, Padovani A, Bonanni L, Mollenhauer B, Schade S, Vandenberghe R, Poesen K, Kramberger MG, Paquet C, Bousiges O, Cretin B, Willemse EAJ, Teunissen CE, Lemstra AW, European-Dementia With Lewy Bodies (E-DLB) ConsortiumFrom the Department of Laboratory Medicine (K.B., E.R.B., E.A.J.W., C.E.T.) and Alzheimer Center Amsterdam (A.A.J.M.U., A.W.L.), Amsterdam UMC, the Netherlands; Department of Quality and Health Technology (M.C.G.), University of Stavanger; The Norwegian Centre for Movement Disorders (M.C.G.) and the Centre for Age-Related Medicine (M.C.G., N.J.A., D.A.), Stavanger University Hospital, Norway; Department of Psychiatry and Neurochemistry (N.J.A., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Old Age Psychiatry (N.J.A., D.A.), King's College London, United Kingdom; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; UK Dementia Research Institute at UCL (H.Z.), London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), Hong Kong, China; Wisconsin Alzheimer's Disease Research Center (H.Z.), University of Wisconsin School of Medicine and Public Health, Madison; Neurology Unit (A.P.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Medicine and Aging Sciences (L.B.), University G. d'Annunzio of Chieti-Pescara, Chieti, Italy; Department of Neurology (B.M.), University Medical Center Göttingen; Paracelsus-Elena-Klinik (B.M., S.S.), Germany; Department of Neurosciences (R.V., K.P.), KU Leuven, Belgium; Department of Neurology and Medical Faculty (M.G.K.), University Medical Center Ljubljana, Slovenia; Department of Neurobiology (M.G.K.), Karolinska Institutet, Huddinge, Sweden; Université de Paris Cité (C.P.), Centre de Neurologie Cognitive, Paris; Laboratory of Biochemistry and Molecular Biology (O.B.), University Hospital of Strasbourg; University of Strasbourg and CNRS (O.B., B.C.); Memory Resource and Research Centre (B.C.), University Hospital of Strasbourg, France; Department of Neurology (E.A.J.W.), Multiple Sclerosis Center; Research Center for Clinical Neuroimmunology and Neuroscience Basel (E.A.J.W.); and Departments of Biomedicine and Clinical Research (E.A.J.W.), University Hospital Basel and University of Basel, Switzerland..
    Neurology; 2024 Jun 25; 102(12):e209418. PubMed ID: 38830138
    [Abstract] [Full Text] [Related]

  • 10. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
    Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, Kramberger MG, Zetterberg H, Mollenhauer B, Boada M, Aarsland D, European DLB Consortium.
    Mov Disord; 2016 Aug 25; 31(8):1203-8. PubMed ID: 27296778
    [Abstract] [Full Text] [Related]

  • 11. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK, Aerts MB, Kuiperij HB, Claassen JAHR, Spies PE, Esselink RAJ, Bloem BR, Verbeek MM.
    Alzheimers Dement; 2014 Jul 25; 10(4):448-455.e2. PubMed ID: 24239248
    [Abstract] [Full Text] [Related]

  • 12. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies.
    Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, van der Flier WM, Sikkes SA.
    J Neurol Neurosurg Psychiatry; 2017 Feb 25; 88(2):113-118. PubMed ID: 27794030
    [Abstract] [Full Text] [Related]

  • 13. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW.
    Alzheimers Res Ther; 2019 Oct 10; 11(1):83. PubMed ID: 31601267
    [Abstract] [Full Text] [Related]

  • 14. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
    Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I.
    J Alzheimers Dis; 2014 Oct 10; 38(1):63-73. PubMed ID: 23948928
    [Abstract] [Full Text] [Related]

  • 15. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM.
    J Alzheimers Dis; 2011 Oct 10; 27(2):377-84. PubMed ID: 21841257
    [Abstract] [Full Text] [Related]

  • 16. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF, Ha J, Chu LW.
    Psychogeriatrics; 2015 Dec 10; 15(4):235-41. PubMed ID: 25533477
    [Abstract] [Full Text] [Related]

  • 17. Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.
    Howard E, Irwin DJ, Rascovsky K, Nevler N, Shellikeri S, Tropea TF, Spindler M, Deik A, Chen-Plotkin A, Siderowf A, Dahodwala N, Weintraub D, Shaw LM, Trojanowski JQ, Vaishnavi SN, Wolk DA, Mechanic-Hamilton D, Morley JF, Duda JE, Grossman M, Cousins KAQ.
    Neurology; 2021 Apr 06; 96(14):e1855-e1864. PubMed ID: 33593865
    [Abstract] [Full Text] [Related]

  • 18. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
    Bousiges O, Bombois S, Schraen S, Wallon D, Quillard MM, Gabelle A, Lehmann S, Paquet C, Amar-Bouaziz E, Magnin E, Miguet-Alfonsi C, Delbeuck X, Lavaux T, Anthony P, Philippi N, Blanc F, ePLM network and collaborators.
    J Neurol Neurosurg Psychiatry; 2018 May 06; 89(5):467-475. PubMed ID: 29321140
    [Abstract] [Full Text] [Related]

  • 19. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
    Vranová HP, Hényková E, Kaiserová M, Menšíková K, Vaštík M, Mareš J, Hluštík P, Zapletalová J, Strnad M, Stejskal D, Kaňovský P.
    J Neurol Sci; 2014 Aug 15; 343(1-2):120-4. PubMed ID: 24928081
    [Abstract] [Full Text] [Related]

  • 20. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier WM, van de Berg WDJ, Teunissen CE, Lemstra AW, El-Agnaf OMA.
    Mov Disord; 2018 Nov 15; 33(11):1724-1733. PubMed ID: 30440090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.